Multi-center validation of the response biomedical corporation RAMP® NT-proBNP assay with comparison to the Roche diagnostics GmbH Elecsys® proBNP assay

被引:23
作者
Lee-Lewandrowski, Elizabeth
Januzzi, James L.
Green, Sandy M.
Tannous, Bakhos
Wu, Alan H. B.
Smith, Andrew
Wong, Alicia
Murakami, MaryAnn M.
Kaczmarek, Jason
Apple, Fred S.
Miller, Wayne L.
Hartman, Karen
Jaffe, Allan S. [1 ]
机构
[1] Mayo Clin, Rochester, MN 55905 USA
[2] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA
[3] San Francisco Gen Hosp, San Francisco, CA 94110 USA
[4] Hennepin Cty Med Ctr, Minneapolis, MN 55415 USA
关键词
NT-proBNP; point-of-care; RAMP (R); biomedical; heart failure; method validation;
D O I
10.1016/j.cca.2007.07.015
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: NT-proBNP measurements aid in the evaluation of patients with suspected heart failure (HF) and may facilitate risk stratification inpatients with HF and acute coronary syndrome (ACS). Point-of-care (POC) assays may provide more timely results and potentially improve patient outcomes. Methods: We evaluated the analytical performance of the Response Biomedical Corporation whole blood RAMP amino-terminal pro-B type natriuretic peptide (NT-proBNP) POC assay compared to the Roche Elecsys proBNP (NT-proBNP) assay. Results: Intra-day and total imprecision (% CV) ranged from 5.5% to 10.3% at 140, 449 and 1675 ng/L. The lowest concentration that yields a 20% CV was 57 ng/L. The lower limit of detection was 18 ng/L. The upper limit of linearity was validated to 23,428 ng/L with an average recovery of 95%. Correlation by Passing and Bablok regression yielded RAMP = 1.01 Elecsys + 14.6, r = 0.98 (n = 540; range of Elecsys values < 5 to >35,000). Concordance of RAMP versus Elecsys using cut-offs of 125 ng/L for subjects < 75 years and 450 ng/L for subjects >= 75 was 92% (95% CI 89-94%) for a group consisting of 127 apparently healthy individuals and 208 non-healthy subjects without HE, and 99% (95% CI 97-100%) for patients with HF, using the New York Heart Association (NYHA) functional classification. Overall, 80%, 87%, 97% and 100% of the RAMP results and 77%, 85%, 96% and 100% of the Elecsys results were greater than the age appropriate cut-off for NYHA I, II, III or IV groups. For both the RAMP and Elecsys results, the median NT-proBNP value was statistically correlated (increasing) with NYHA I, II, III or IV groups, respectively (p < 0.0001), with no significant difference between the two methods. Conclusions: The POC Response Biomedical RAMP NT-proBNP assay provides comparable results that measured on the FDA cleared Roche Elecsys central laboratory platform, (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:20 / 24
页数:5
相关论文
共 4 条
[1]   N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease [J].
Bibbins-Domingo, Kirsten ;
Gupta, Reena ;
Na, Beeya ;
Wu, Alan H. B. ;
Schiller, Nelson B. ;
Whooley, Mary A. .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2007, 297 (02) :169-176
[2]  
Green SM, 2007, ARCH PATHOL LAB MED, V131, P473
[3]   The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study [J].
Januzzi, JL ;
Camargo, CA ;
Anwaruddin, S ;
Baggish, AL ;
Chen, AA ;
Krauser, DG ;
Tung, R ;
Cameron, R ;
Nagurney, JT ;
Chae, CU ;
Lloyd-Jones, DM ;
Brown, DF ;
Foran-Melanson, S ;
Sluss, PM ;
Lee-Lewandrowski, EL ;
Lewandrowski, KB .
AMERICAN JOURNAL OF CARDIOLOGY, 2005, 95 (08) :948-954
[4]   Amino-terminal pro-brain natriuretic peptide, brain natriuretic peptide, and troponin T for prediction of mortality in acute heart failure [J].
Sakhuja, Rahul ;
Green, Sandy ;
Oestreicher, Eveline M. ;
Sluss, Patrick M. ;
Lee-Lewandrowski, Elizabeth ;
Lewandrowski, Kent B. ;
Januzz, James L., Jr. .
CLINICAL CHEMISTRY, 2007, 53 (03) :412-420